Milukante (Montelukast)

Milukante (montelukast) acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

• Asthma: Reduces frequency and severity of asthma attacks by preventing bronchoconstriction.
• Allergic rhinitis: Alleviates nasal congestion, sneezing, and itching associated with seasonal allergies.
• Exercise‑induced bronchoconstriction: Prevents airway narrowing triggered by physical activity, improving exercise tolerance.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells, and eosinophils. By antagonizing this receptor, it inhibits leukotriene‑mediated bronchoconstriction, vascular permeability, and inflammatory cell recruitment, thereby reducing airway edema and hyper‑responsiveness associated with asthma and allergic rhinitis. The inhibition also diminishes the release of pro‑inflammatory mediators, contributing to long‑term control of chronic respiratory airway.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Abdominal pain: discomfort or cramps in the stomach area.
• Cough: non‑productive cough without fever.
• Diarrhea: loose stools occurring intermittently.
• Nasopharyngitis: mild upper respiratory tract infection symptoms.
• Rash: mild skin redness or itching.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention.
• Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes.
• Severe allergic reactions: anaphylaxis with hives, breathing difficulty, or shock.
• Neuropsychiatric events: agitation, depression, or suicidal thoughts.
• Blood dyscrasias: unexplained bruising or low blood cell counts.

Before prescribing Milukante, clinicians should consider several precautionary measures to ensure patient safety.

• Assess medical history: review asthma severity, liver disease, and prior hypersensitivity reactions.
• Monitor psychiatric symptoms: observe for mood changes, depression, or suicidal ideation.
• Evaluate drug interactions: check concomitant use of CYP3A4 inhibitors or other leukotriene modifiers.
• Use in pregnancy: prescribe only if benefits outweigh potential risks, after consulting obstetric guidance.
• Use in lactation: consider infant exposure through breast milk and assess necessity.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase montelukast plasma levels, raising risk of adverse effects.
• Rifampin: induces metabolism, potentially reducing therapeutic efficacy.

Moderate Interactions (Monitor Closely)

• Phenobarbital: may lower drug concentrations, requiring clinical monitoring.
• Antidepressants (e.g., fluoxetine): possible additive neuropsychiatric effects.
• Other leukotriene pathway agents (e.g., zafirlukast): combined use may increase risk of liver toxicity.
• Oral contraceptives: may slightly increase montelukast exposure, monitor for side effects.